The major drivers driving the growth of the global acute kidney injury (AKI) disease treatment market include the growing elderly population, the prevalence of chronic diseases, and a growing number of acute care admissions and emergency department admissions leading to ICU admission. North America and Europe are expected to hold a significant market share due to the high disease prevalence and other chronic disease prevalence which may lead to acute kidney disease while the Asia Pacific with Japan, having the maximum geriatric population in the world is expected to be the fastest-growing. In addition, rising health awareness among people, especially in developing countries will lead to frequent check-ups, emanating the market growth owing to early disease detection followed by treatment during the forecast period and beyond.
|Market size value in 2019||US$29.612 billion|
|Market size value in 2025||US$31.600 billion|
|Growth Rate||CAGR of 1.09% from 2019 to 2025|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Diagnosis, Type of RRT, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Exponential Biotherapies, Inc., NIKKISO AMERICA, INC., AM-Pharma, RenalGuard Solutions, Inc., Angion Biomedica Corp., Thrasos Therapeutics Inc., AtoxBio, Sentien Biotechnologies, Inc.|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What will be the acute kidney injury (AKI) disease treatment market size by 2025?
A1. The acute Kidney Injury (AKI) Disease Treatment market is expected to reach a total market size of US$31.600 billion by 2025.
Q2. What are the growth prospects for the acute kidney injury disease treatment market?
A2. The global acute kidney injury disease treatment market is expected to grow at a CAGR of 1.09% during the forecast period.
Q3. What is the size of the global acute kidney injury (AKI) disease treatment market?
A3. The acute kidney injury disease treatment market was valued at US$29.612 billion in 2019.
Q4. What factors are anticipated to drive acute kidney injury disease treatment market growth?
A4. The major drivers driving the growth of the global acute kidney injury (AKI) disease treatment market include the growing elderly population, the prevalence of chronic diseases, and a growing number of acute care admissions and emergency department admissions leading to ICU admission.
Q5. Which region holds the largest market share in the acute kidney injury disease treatment market?
A5. North America and Europe are expected to hold a significant share of the acute kidney injury (AKI) disease treatment market.
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5.1. By age group
4.5.2. By gender
4.5.3. By region
4.6. Product Pipeline
5. ACUTE KIDNEY INJURY (AKI) DISEASE TREATMENT MARKET BY DIAGNOSIS
5.1. Urine Tests
5.2. Blood Tests
5.3. Glomerular Filtration Rate (GFR)
5.4. Imaging Tests
5.5. Kidney Biopsy
6. ACUTE KIDNEY INJURY (AKI) DISEASE TREATMENT MARKET BY TYPE OF RRT
7. ACUTE KIDNEY INJURY (AKI) DISEASE TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.2. South America
7.3.3. United Kingdom
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.5. Asia Pacific
7.5.3. South Korea
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Exponential Biotherapies, Inc.
9.2. NIKKISO AMERICA, INC.
9.4. RenalGuard Solutions, Inc.
9.5. Angion Biomedica Corp.
9.6. Thrasos Therapeutics Inc.
9.8. Sentien Biotechnologies, Inc.
LIST OF FIGURES
LIST OF TABLES
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.